A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Latest Information Update: 23 Oct 2023
Price :
$35 *
At a glance
- Drugs Sipuleucel-T (Primary) ; Enzalutamide
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms STRIDE
- Sponsors Dendreon Corporation
- 15 Feb 2020 Results assessing association of humoral antigen spread with cytotoxic T lymphocyte activity after sipuleucel-T treatment in two studies (STAMP and STRIDE), presented at the 2020 Genitourinary Cancers Symposium.
- 13 Feb 2020 Results published in the Dendreon corporation media release
- 13 Feb 2020 According to a Dendreon corporation media release, results from STAMP and STRIDE studies assessing the association of humoral antigen spread (AgS) with cytotoxic T lymphocyte (CTL) activity were presented at the 2020 ASCO Genitourinary (GU) Cancers Symposium in San Francisco.